Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Actelion Sweetens Shareholders With Maiden Dividend

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

The Swiss biotech continues to defend its independence, appeasing investors with promise of regular dividends.

You may also be interested in...



Actelion CEO Seeks To Rebuild Investor Confidence As Pressure Builds On Tracleer

CEO Jean-Paul Clozel is seeking to rebuild investor confidence in the wake of the company's year-long run-in with activist shareholder Elliott Advisors.

Actelion Management Re-Shuffle Reflects Continued Activist Pressure

Changes include new COO role, new business development chief and spinning off non-core assets.

Actelion Management Re-Shuffle Reflects Continued Activist Pressure

Changes include new COO role, new business development chief and spinning off non-core assets.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
In Vivo

Topics

Tags:
BioPharmaceutical
Latest Headlines

Global Pharma Guidance Tracker – March 2024

EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

See All
UsernamePublicRestriction

Register

PS071846

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By